Drug Approval | February 14, 2022
Lilly's bebtelovimab receives EUA to treat mild-to-moderate Covid-19
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Key takeaways of recent quarter & conference call highlights
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
On track to complete the BLA submission in the first half of 2022
Subscribe To Our Newsletter & Stay Updated
